比尼替尼

Binimetinib

询价 10g/瓶起订

5g/瓶起订

2g/瓶起订

山东更新日期：2025-12-26

山东轩鸿生物医药有限公司

非会员

联系人：刘文锋

手机：15154197770 拨打

邮箱：2184188971@qq.com

产品详情:

中文名称：: 比尼替尼

英文名称：: Binimetinib

CAS号：: 606143-89-9

纯度规格：: 99

产品类别：: 原料药

Binimetinib (MEK162, ARRY-162) is a MEK inhibitor being developed by Array Biopharma to treat various cancers.
It can be taken orally in tablet form.
In 2015 it was in phase 3 clinical trials for ovarian cancer, BRAF mutant melanoma, and NRAS Q61 mutant melanoma.
In Dec 2015 the company announced that the mutant-NRAS melanoma trial was successful. In the trial, those receiving binimetinib had a median progression-free survival of 2.8 months versus 1.5 months for those on the standard dacarbazine treatment. NDA submitted Jun 2016.
In April 2016 it was reported that the phase III trial for low-grade ovarian cancer was terminated due to lack of efficacy.

基本信息

▼

▲

中文名称

比尼替尼

英文名称

Binimetinib

中文别名

英文别名

ARRY-438162;6-(4-bromo-2-fluoroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide;6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethoxy)amide;MEK-162;6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid-(2-hydroxyethyoxy)amide;

查看更多英文别名

CAS号

606143-89-9

分子式

C17H15BrF2N4O3

分子量

441.22700

精确质量

440.03000

PSA

91.90000

LOGP